CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD)
Clinical trials for CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) explained in plain language.
Never miss a new study
Get alerted when new CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) trials appear
Sign up with your email to follow new studies for CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for GVHD patients: experimental drug vimseltinib enters phase 2 trial
Disease control Recruiting nowThis study tests whether the drug vimseltinib is safe and effective for adults with moderate to severe chronic graft-versus-host disease (cGVHD), a complication after a stem cell transplant. Participants must have already tried at least two other treatments without success. They …
Matched conditions: CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD)
Phase: PHASE2 • Sponsor: Deciphera Pharmaceuticals, LLC • Aim: Disease control
Last updated Jun 17, 2026 05:43 UTC
-
New hope for GVHD patients: ruxolitinib tested as First-Line therapy
Disease control Recruiting nowThis study compares two drugs, ruxolitinib and prednisone, as the first treatment for chronic graft-versus-host disease (cGVHD), a complication after bone marrow transplant. About 120 adults who need systemic therapy for cGVHD will be randomly assigned to receive one of the two d…
Matched conditions: CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD)
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated May 26, 2026 12:02 UTC